Literature DB >> 30566997

[Cold Plasma to Treat Therapy-Refractive Corneal Ulcers].

Helena Reitberger1, Emilio Martines2, Andreas Mohr3, Catherine Chow3, Thomas Fuchsluger1,4.   

Abstract

BACKGROUND: The integrity of the ocular surface and the transparency of the cornea is crucial to obtain a good visual acuity - a requirement to actively participate in both social and professional environments. The homeostasis of the ocular surface is constantly endangered by microbes and by intrinsic factors with negative influence on wound healing. Furthermore, widespread use of contact lenses obtain a risk of corneal infection even resulting in corneal perforation and loss of the eye. Current therapies include topical and systemic antibiotics and antimycotics, often applied in an in-ward setting. PATIENTS/
MATERIALS AND METHODS: Some microbes can be therapy-resistent or -refractory and therefore cause a deterioration of the clinical aspect. In this study, the effects of cold plasma treatment of corneal ulcers on reduction of microbial load in vitro, in tissue ex vivo and in a therapy-refractory ulcer.
RESULTS: In vitro, ex vivo and in the patient microbial load could be reduced or the clinical findings improved.
CONCLUSIONS: Plasma medicine and its disinfective properties could open a novel approach to treat microbial infections of the cornea. The can result in reduced treatment times, a faster demission of the patients and overall in a reduction of health care costs. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30566997     DOI: 10.1055/a-0792-1301

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  1 in total

1.  The assessment of the concentration of candidate cytokines in response to conjunctival-exposure of atmospheric low-temperature plasma in an animal model.

Authors:  Farhad Nejat; Khosrow Jadidi; Hosein Aghamollaei; Mohammad Amin Nejat; Nazanin-Sadat Nabavi; Shima Eghtedari
Journal:  BMC Ophthalmol       Date:  2021-12-04       Impact factor: 2.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.